Anakinra

• Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study. Pending
  2024-518125-15-00 Phase II 1 country Azienda Sanitaria Universitaria Friuli Centrale
• ESTIS trial: Early Stop of targeted Treatment in children with Systemic JIA. Pending
  2024-518684-35-00 Phase IV 1 country Universitair Medisch Centrum Utrecht
• PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending
  2025-521371-31-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS Pending
  2025-521478-32-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment Pending
  2025-523921-17-00 Phase II 1 country Centre Hospitalier Regional Et Universitaire De Brest
• THRILL: Treat Hyperinflammation in child oncology study Pending
  2025-524541-27-00 Phase II 1 country Prinses Maxima Centrum voor Kinderoncologie B.V.
• IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO) Pending
  2025-524834-24-00 Phase I/II 1 country Centre Hospitalier Universitaire De Nantes
• Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation: t… Recruiting
  2023-508123-12-00 Phase II/III 4 countries Hellenic Institute For The Study Of Sepsis
• ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RET… Recruiting
  2024-516244-25-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial Recruiting
  2024-517230-17-00 Phase II 1 country Stichting Radboud universitair medisch centrum
• Randomized controlled trial in patients on long-term colchicine with colchicine-resistant familial Mediterranean fever (FMF) to evaluate the… Recruiting
  2023-506721-11-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting
  2022-501725-21-00 Phase I 1 country Universitaet Muenster
• Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroi… Recruiting
  2023-504756-96-00 Phase III 1 country Giannina Gaslini Institute For Scientific Hospitalization And Care
• Targeted therapy with anakinra for dilated cardiomyopathy: phase IIa randomized double blind monocentric clinical trial to evaluate the effi… Recruiting
  2024-514861-21-00 Phase II 1 country Ospedale San Raffaele S.r.l.
• A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutaneous administration o… Recruiting
  2023-510376-31-00 Phase II 1 country Universitaetsklinikum Heidelberg AöR
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended
  2024-512998-27-00 Phase III 15 countries Genmab A/S
• Effect of different drugs on the immune response during inflammation: the DEDICATE-LPS study Ended
  2023-506556-24-00 Phase II 1 country Stichting Radboud University Medical Center
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended
  2023-504830-23-00 Phase III 13 countries Genmab A/S
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended
  2023-504805-35-00 Phase I/II 10 countries Genmab A/S
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended
  2023-504802-12-00 Phase I (FiH) 9 countries Genmab A/S
• PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended
  2024-513647-86-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended
  2023-504832-16-00 Phase II 8 countries Genmab A/S
• Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease… Ended
  2024-514347-28-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo-controlled, randomized clinical trial to evaluate the e… Ended
  2024-515472-13-00 Phase II 1 country Ospedale San Raffaele S.r.l.

Showing 1–24 of 24 trials